Cargando…
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
Rationale To investigate whether the mutational landscape of circulating cell-free DNA (cfDNA) could predict and dynamically monitor the response to first-line platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods Eligible patients were included and blood...
Autores principales: | Jiang, Tao, Li, Xuefei, Wang, Jianfei, Su, Chunxia, Han, Wenbo, Zhao, Chao, Wu, Fengying, Gao, Guanghui, Li, Wei, Chen, Xiaoxia, Li, Jiayu, Zhou, Fei, Zhao, Jing, Cai, Weijing, Zhang, Henghui, Du, Bo, Zhang, Jun, Ren, Shengxiang, Zhou, Caicun, Yu, Hui, Hirsch, Fred R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706097/ https://www.ncbi.nlm.nih.gov/pubmed/29187901 http://dx.doi.org/10.7150/thno.21687 |
Ejemplares similares
-
Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020) -
Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020) -
Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017) -
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019) -
Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression
por: Sestokaite, Agne, et al.
Publicado: (2023)